Association of paraoxonase-1 M55L genotype and alcohol consumption with coronary atherosclerosis: The Helsinki Sudden Death Study

Pharmacogenetics

Volumn 14, Issue 8, 2004, Pages 479-485

  Rontu, Riikka ^a   Lehtimäki, Terho ^a   Ilveskoski, Erkki ^a,b   Mikkelsson, Jussi ^b   Kajander, Olli ^b   Goebeler, Sirkka ^b   Perola, Markus ^c   Penttilä, Antti ^d   Karhunen, Pekka J ^b  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Alcohol; Autopsy study; Coronary artery disease; Genotype; Paraoxonase 1

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; FAT; LEUCINE; METHIONINE; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALLELE; ARTICLE; ATHEROSCLEROTIC PLAQUE; AUTOPSY; CARDIOVASCULAR RISK; CONCENTRATION RESPONSE; CONSUMER; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE SEVERITY; FRIEND; GENETIC ASSOCIATION; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; PRIORITY JOURNAL; RELATIVE; RISK FACTOR; STAINING; STATISTICAL SIGNIFICANCE;

ADULT; AGED; ALCOHOL DRINKING; AMINO ACID SUBSTITUTION; ARYLDIALKYLPHOSPHATASE; AUTOPSY; CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; FINLAND; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LEUCINE; MALE; METHIONINE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 4143051238     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fpc.0000114746.08559.00     Document Type: Article

References (45)

1. Marmot MG, Rose G, Shipley MJ, Thomas BJ. Alcohol and mortality: a U-shaped curve. Lancet 1981; 1:580-583.
2. Klatsky AL, Friedman GD, Siegelaub AB. Alcohol use and cardiovascular disease: the Kaiser-Permanente experience. Circulation 1981; 64: III 32-41.
3. Malmendier CL, Delcroix C. Effect of alcohol intake on high and low density lipoprotein metabolism in healthy volunteers. Clin Chim Acta 1985; 152:281-288.
4. Tall AR. An overview of reverse cholesterol transport. Eur Heart J 1998; 19:A31-A35.
5. Rosenson RS. Beyond low-density lipoprotein cholesterol. A perspective on low high-density lipoprotein disorders and Lp(a) lipoprotein excess. Arch Intern Med 1996; 156:1278-1284.
6. Hessler JR, Robertson AL Jr, Chisolm GM III. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis 1979; 32:213-229.
7. Mackness MI, Abbott CA, Arrol S, Durrington PN. The role of high-density and lipid soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J 1993; 294:829-835.
8. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995; 96:2882-2891.
9. Sierksma A, van der Gaag MS, van Tol A, James RW, Hendriks HF. Kinetics of HDL cholesterol and paraoxonase activity in moderate alcohol consumers. Alcohol Clin Exp Res 2002; 26:1430-1435.
10. van der Gaag MS, van Tol A, Scheek LM, James RW, Urgert R, Schaafsma G, et al. Daily moderate alcohol consumption increases serum paraoxonase activity; a diet-controlled, randomised intervention study in middle-aged men. Atherosclerosis 1999; 147:405-410.
11. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Eng J Med 1989; 320:915-924.
12. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN, Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998; 101:1581-1590.
13. Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, et al. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 2000; 101: 2510-2517.
14. Hernandez AF, Pla A, Valenzuela A, Gil F, Hougen HP, Villanueva E. Paraoxonase activity in human pericardial fluid: its relationship to coronary artery disease. Int J Legal Med 1993; 105:321-324.
15. Mackness MI, Mackness B, Durrington PN, Fogelman AM, Berliner J, Lusis AJ, et al. Paraoxonase and coronary heart disease. Curr Opin Lipidol 1998; 9:319-324.
16. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nature Genet 1993; 3:73-76.
17. Garin MC, James RW, Dussoix P, Blanche H, Passa P, Froguel P, et al. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 1997; 99:62-66.
18. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the molecular polymorphisms of human paraoxonase (PON 1) on the rate of hydrolysis of paraoxon. Br J Pharmacol 1997; 122:265-268.
19. Shih DM, Gu L, Hama S, Xia YR, Navab M, Fogelman AM, et al. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest 1996; 97:1630-1639.
20. Nishio E, Watanabe Y. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols. Biochem Biophys Res Commun 1997; 236:289-293.
21. Isola J, DeVries S, Chu L, Ghazvini S, Waldman F. Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples. Am J Pathol 1994; 145:1301-1308.
22. Ilveskoski E, Perola M, Lehtimaki T, Laippala P, Savolainen V, Pajarínen J, et al. Age-dependent association of apolipoprotein E genotype with coronary and aortic atherosclerosis in middle-aged men: an autopsy study. Circulation 1999; 100:608-613.
23. Salonen JT, Malin R, Tuomainen TP, Nyyssönen K, Lakka TA, Lehtimaki T. Polymorphism in high density lipoprotein paraoxonase gene and risk of acute myocardial infarction in men: prospective nested case-control study. BMJ 1999; 21:487-489.
24. Malin R, Rantalaiho V, Huang XH, Wirta O, Pasternack A, Leinonen JS, et al. Association between M/L55-polymorphism of paraoxonase enzyme and oxidative DNA damage in patients with type 2 diabetes mellitus and in control subjects. Hum Genet 1999; 105:179-180.
25. Mackness MI, Arrol S, Mackness B, Durrington PN. Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation. Lancet 1997; 349:851-852.
26. Serrato M, Marian AJ. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest 1995; 96:3005-3008.
27. Sanghera DK, Aston CE, Saha N, Kamboh MI. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet 1998; 62:36-44.
28. Zama T, Murata M, Matsubara Y, Kawano K, Aoki N, Yoshino H, et al. A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol 1997; 17:3565-3569.
29. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21:473-480.
30. Leviev I, Negro F, James RW. Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler Thromb Vasc Biol 1997; 17:2935-2939.
31. Meagher EA, Barry OP, Burke A, Lucey MR, Lawson JA, Rokach J, et al. Alcohol-induced generation of lipid peroxidation products in humans. J Clin Invest 1999; 104:805-813.
32. Reinke LA, Lai EK, DuBose CM, McCay PB. Reactive free radical generation in vivo in heart and liver of ethanol-fed rats: correlation with radical formation in vitro. Proc Natl Acad Sci USA 1987; 84:9223-9227.
33. Oh SI, Kim CI, Chun HJ, Park SC. Chronic ethanol consumption affects glutathione status in rat liver. J Nutr 1998; 128:758-763.
34. Siler SQ, Neese RA, Hellerstein MK. De novo lipogenesis, lipid kinetics, and whole-body lipid balances in humans after acute alcohol consumption. Am J Clin Nutr 1999; 70:928-936.
35. Friedman LA, Kimball AW. Coronary heart disease mortality and alcohol consumption in Framingham. Am J Epidemiol 1986; 124:481-489.
36. Rimm EB, Klatsky A, Grobbee D, Stampfer MJ. Review of moderate alcohol consumption and reduced risk of coronary heart disease: is the effect due to beer, wine, or spirits. BMJ 1996; 312:731-736.
37. Gaziano JM, Buring JE, Breslow JL, Goldhaber SZ, Rosner B, VanDenburgh M, et al. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N Engl J Med 1993; 329:1829-1834.
38. Luoma PV, Sotaniemi EA, Pelkonen RO. Alcohol, HDL cholesterol, and liver microsomal induction. Lancet 1984; 1:47.
39. Mackness MI, Durrington PN. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995; 115:243-253.
40. Blatter MC, James RW, Messmer S, Barja F, Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem 1993; 211:871-879.
41. Rao MN, Marmillot P, Gong M, Palmer DA, Seeff LB, Strader DB, et al. Light, but not heavy alcohol drinking, stimulates paraoxonase by upregulating liver mRNA in rats and humans. Metabolism 2003; 52: 1287-1294.
42. Leviev I, Deakin S, James RW. Decreased stability of the M54 isoform of paraoxonase as a contributory factor to variations in human serum paraoxonase concentrations. J Lipid Res 2001; 42:528-535.
43. Karhunen PJ, Penttila A. Validity of post-mortem alcohol reports. Alcohol Alcohol 1990; 25:25-32.
44. Kiechl S, Willeit J, Rungger G, Egger G, Oberhollenzer F, Bonora E. Alcohol consumption and atherosclerosis: what is the relation? Prospective results from the Bruneck Study. Stroke 1998; 29:900-907.
45. Taskinen MR, Valimaki M, Nikkila EA, Kuusi T, Ylikahri R. Sequence of alcohol-induced initial changes in plasma lipoproteins (VLDL and HDL) and lipolytic enzymes in humans. Metabolism 1985; 34:112-119.